Hilde Furberg

Directeur/Membre du Conseil chez PCI BIOTECH HOLDING ASA Fortune : 6 624 $ au 31/05/2026

Profil

Hilde Furberg currently works at PCI Biotech Holding ASA, as Independent Director from 2019, Herantis Pharma Oyj, as Independent Director from 2021, Sedana Medical AB, as Director from 2022, Pluvia AS, as Director, and Sanofi BV, as SVP-Personalized Genetic Health Europe from 2002.
Ms. Furberg also formerly worked at Blueprint Genetics Oy, as Chairman, Calliditas Therapeutics AB, as Chairman from 2015 to 2016, Probi AB, as Independent Director in 2011, Copenhagen Capacity, as Director, Pronova BioPharma ASA, as Director from 2011 to 2013, Weifa ASA, as Independent Director from 2012 to 2013, Algeta ASA, as Non-Executive Director from 2013 to 2014, BerGenBio ASA, as Independent Non-Executive Director from 2017 to 2019, Larkberget AB, as Director, Bio-Me AS, as Director, Tappin AS, as Director, OncoZenge AB, as Director from 2020 to 2023, Genzyme Corp., as Senior Vice President & European Head-Rare Disease from 2010 to 2018, Baxter Medical AB, as General Manager, Genzyme Therapeutics Ltd., as Head-Rare Diseases Europe, and J&J Future Invest AS, as Partner.
Ms. Furberg received her graduate degree in 1980 from the University of Oslo.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
SEDANA MEDICAL AB 0,01%	10/11/2025	6 500 ( 0,01% )	6 624 $	31/05/2026

Postes actifs de Hilde Furberg

Sociétés	Poste	Début
PCI BIOTECH HOLDING ASA	Directeur/Membre du Conseil	01/05/2019
HERANTIS PHARMA OYJ	Directeur/Membre du Conseil	15/04/2021
SEDANA MEDICAL AB	Directeur/Membre du Conseil	01/01/2022
Pluvia AS	Directeur/Membre du Conseil	-
Genzyme Europe BV	Corporate Officer/Principal	14/10/2011

Anciens postes connus de Hilde Furberg

Sociétés	Poste	Fin
ONCOZENGE AB	Directeur/Membre du Conseil	21/08/2023
ONCOINVENT ASA	Président	06/01/2017
J&J Future Invest AS	Corporate Officer/Principal	13/11/2018
Genzyme Corp.	Corporate Officer/Principal	01/11/2018
░░░░░░ ░░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	░░░░░░░░░░